Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistanceopen access
- Authors
- Kim, Hyungjoo; Choi, Je-Min; Lee, Kyung-min
- Issue Date
- May-2022
- Publisher
- MDPI
- Keywords
- immune checkpoint blockade; resistance; TNBC
- Citation
- Biomedicines, v.10, no.5, pp.1 - 17
- Indexed
- SCIE
SCOPUS
- Journal Title
- Biomedicines
- Volume
- 10
- Number
- 5
- Start Page
- 1
- End Page
- 17
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138618
- DOI
- 10.3390/biomedicines10051130
- ISSN
- 2227-9059
- Abstract
- Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating immune cells, render the immunogenic phenotypes. Consequently, TNBCs have shown durable responses to ICBs such as atezolizumab and pembrolizumab in clinic. However, a significant number of TNBC patients do not benefit from these therapies, and mechanisms of resistance are poorly understood. Here, we review biomarkers that predict the responsiveness of TNBCs to ICB and recent advances in delineating molecular mechanisms of resistance to ICBs.
- Files in This Item
-
- Appears in
Collections - 서울 자연과학대학 > 서울 생명과학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/138618)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.